Brought to you by 
Fidelity leads oversubscribed $55mm Series C round for Afferent
22 Dec 2020
Executive Summary
Afferent Pharmaceuticals Inc. (cardiology, respiratory, neurology, and urology targets in C-fiber primary afferent nerves) closed an oversubscribed $55mm Series C round led by new backer Fidelity Management & Research and including other first-time shareholders Jennison Associates, Partner Fund Management, Redmile Group, Tekla Healthcare Investors, Tekla Life Science Investors, and a blue chip investment fund, plus existing investor New Leaf Ventures.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Fidelity leads oversubscribed $55mm Series C round for Afferent
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice